0001209191-23-028884.txt : 20230511
0001209191-23-028884.hdr.sgml : 20230511
20230511211353
ACCESSION NUMBER: 0001209191-23-028884
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230509
FILED AS OF DATE: 20230511
DATE AS OF CHANGE: 20230511
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SEIDENBERG BETH C
CENTRAL INDEX KEY: 0001184592
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41696
FILM NUMBER: 23912900
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACELYRIN, Inc.
CENTRAL INDEX KEY: 0001962918
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 852406735
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4149 LIBERTY CANYON RD.
CITY: AGOURA HILLS
STATE: CA
ZIP: 91301
BUSINESS PHONE: 805-871-4300
MAIL ADDRESS:
STREET 1: 4149 LIBERTY CANYON RD.
CITY: AGOURA HILLS
STATE: CA
ZIP: 91301
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-09
0
0001962918
ACELYRIN, Inc.
SLRN
0001184592
SEIDENBERG BETH C
C/O ACELYRIN, INC.
4149 LIBERTY CANYON RD.
AGOURA HILLS
CA
91301
1
0
1
0
0
Common Stock
2023-05-09
4
C
0
8540729
A
8540729
I
See footnote
Common Stock
2023-05-09
4
P
0
1250000
18.00
A
9790729
I
See footnote
Common Stock
2023-05-09
4
P
0
60000
18.00
A
60000
D
Series A Redeemable Convertible Preferred Stock
2023-05-09
4
C
0
4056795
D
Common Stock
4056795
0
I
See footnote
Series B Redeemable Convertible Preferred Stock
2023-05-09
4
C
0
2445786
D
Common Stock
2445786
0
I
See footnote
Series C Redeemable Convertible Preferred Stock
2023-05-09
4
C
0
2038148
D
Common Stock
2038148
0
I
See footnote
Director Stock Option (right to buy)
18.00
2023-05-09
4
J
0
23243
0.00
D
2033-05-03
Class A Common Stock
23243
0
D
Director Stock Option (right to buy)
18.00
2023-05-09
4
J
0
23243
0.00
A
2033-05-03
Common Stock
23243
23243
D
Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration.
Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any.
Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the "IPO").
Represents shares of Common Stock purchased through a directed share program in the IPO.
Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock.
Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
/s/ Mina Kim, Attorney-in-fact
2023-05-11